News
- The “β2GPI Neoself Antibody Test,” a Novel Test for RPL and RIF, Now Launched in Malaysia
- AOI Biosciences and Sumitomo Corporation Launches β2GPI Neo-Self Antibody Test in Indonesia
~ Joint Research Agreement Signed with Hermina Group ~ - β2GPI Neoself Antibody Test Recognized as Advanced Medical Care by the Japanese Ministry of Health, Labour and Welfare
Our Science-based Platforms
Neoself Platform
AOI Bio. leverages a newly discovered mechanism, called Neoself, underlying autoimmune diseases to provide diagnostic services and support drug development efforts.
We currently offer testing services for the Anti-B2GPI Neoself Antibody in patients with
unexplained recurrent pregnancy or implantation failures.
Bioinformatics Analysis Platform
AOI Bio. employs advanced computational processing to help search for novel biomarkers and drug candidates.
We utilize the quantum-inspired optimization solution SQBM+, provided by our advanced computing partner Toshiba Digital Solutions, to identify allosteric pockets for drug development.
Company Information
| Company name | AOI Biosciences Inc. |
|---|---|
| Address |
【Headquarters･Neoself Testing Lab】 Saito Bio Innovation Center 2F, 7-7-20 Saito-Asagi, Ibaraki-shi, Osaka, 567-0085 【Suita Office】 Research Institute for Microbial Diseases, The University of Osaka, 3-1 Yamadaoka, Suita-shi, Osaka, 565-0871 |
| Establish | November 2019 |
| Board Members |
|
| Advisors |
|